Publications
57
Citations
76
Est. group size
~24
Recurring co-author estimate
Active years
6
Publishing since 2021
Samon Benrashid's research focuses on chronic lymphocytic leukemia (CLL), a type of blood cancer, with particular attention to how patients respond and become resistant to targeted drug treatments like ibrutinib (a BTK inhibitor). Recent work uses single-cell RNA sequencing, a technique that examines gene activity in individual cells, to characterize how leukemia cells and immune T-cells change during treatment. This work aims to identify why some patients' cancers stop responding to therapy and how treatment affects the immune system.
Publication output was minimal or absent for most of the past decade but shows a sharp recent increase, with a large spike in 2026 following modest activity in 2023-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia
Current Hematologic Malignancy Reports · 2026
- Abstract 1509: Cost-effective, full-length transcriptome of chronic lymphocytic leukemia patient cd8 t cells reveals the impact of BTKi treatment on mRNA processing and gene expression
Cancer Research · 2026
- Abstract 7278: Single-cell RNA-seq analysis reveals distinct tumor and immunosuppressive T-cell phenotypes in CLL patients treated with ibrutinib
Cancer Research · 2026
- Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Clinical Cancer Research · 2026
- Supplementary Table S4 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026
- Supplementary Figure S7 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026
- Supplementary Table S3 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026
- Supplementary Table S5 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026
- Data from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026
- Supplementary Table S1 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026
- Supplementary Figure S3 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026
- Supplementary Figure S2 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026
- Supplementary Figure S1 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026
- Supplementary Figure S4 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026
- Supplementary Table S8 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026
- Blood×13
- Cancer Research×2
- Experimental Hematology and Oncology×1
- iScience×1
- Blood Cancer Discovery×1
- Shrilekha Misra
Medicine · The Ohio State University
- Alexander Marr
Medicine · The Ohio State University
- Janani Ravikrishnan
Medicine · The Ohio State University
- Andrew D. Mitchell
Medicine · The Ohio State University
- Jazmin Urrutia
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile